Search This Blog

Monday, March 2, 2026

Russia's Key Novorossiysk Export Hub Again Pounded In Large Ukrainian Drone Wave

 Iran is understandably dominating global headlines, but major events are still happening in oh yeah that other war which has been raging for four plus years in eastern Europe.

Like with the Iran conflict theatre, major geopolitical repercussions impacting energy oil prices are coming out of the Ukraine war. An overnight Monday large-scale drone wave from Ukraine has severely damaged Russia's Black Sea port of Novorossiysk.

Image: stock.adobe

Ukraine's General Staff has described that the facility supplies Russian forces engaged in the war, after reports have indicated the intended target was the Sheskharis oil terminal, one of southern Russia's largest oil and petroleum transshipment hubs.

A large fire was observed in the wake of the attack on the key oil export site. But civilian neighborhoods were also damaged in the assault, with debris from intercepted drones reportedly hitting multiple residential structures in the city, resulting in several hospitalizations of residents. 

The attack was significant enough to force air travel delays and cancelations over much of southern Russia, including international routes to Istanbul. Routes to Tel Aviv and the Gulf have already been disrupted due to Trump's 'Operation Epic Fury' targeting Iran.

As for this latest drone attack among many targeting Russian oil sites of late, the Security Service of Ukraine (SBU) has owned up to it, saying, "together with other components of the Defense Forces, struck Russian warships, air defense systems, and oil infrastructure in the port of Novorossiysk."

According to more details via Reuters:

Russia said on Monday that five people had been injured, 20 buildings damaged, and a fire at a fuel terminal extinguished after what it said was a massive overnight Ukrainian drone attack on the Black Sea port city of Novorossiysk.

An official at Ukraine's SBU security service said Ukrainian drones had struck the Sheskharis oil terminal at the port, hitting six of its seven loading facilities, and that Russian warships had also been hit. Ukraine's General Staff said a naval base had also been struck, along with an S-400 air defense radar station.

Prior such Ukrainian attacks on Novorossiysk have caused oil prices to briefly spike; however, at the moment Iran war related sentiment and fast-moving events in the Hormuz Strait dominate.

We've featured before of Russia's largest Black Sea oil export terminal:  Novorossiysk handles a major share of Russia's seaborne crude exports, including Urals and CPC Blend. When it goes offline, millions of barrels per day are at risk.

https://www.zerohedge.com/energy/russias-key-novorossiysk-export-hub-again-pounded-large-ukrainian-drone-wave

ClearPoint: uniQure's FDA rejection of AMT-130 data sparked sympathy premarket plunge.

 


uniQure ($QURE) disclosed FDA feedback stating Phase I/II data for its Huntington's gene therapy AMT-130—delivered via ClearPoint Neuro's platform—was insufficient without a prospective, randomized, sham-controlled Phase 3 trial. Released early March 2, this news fueled fears over regulatory hurdles for CLPT-enabled brain delivery programs, amplifying negative sentiment amid recent declines (e.g., -12.89% prior session). Premarket volume reflected algo and retail selling, extending multi-day weakness ahead of Q4 earnings on March 4. Posts from financial commentators highlighted the partnership risk.


https://finviz.com/quote.ashx?t=CLPT&p=d

Pulmatrix says Cullgen terminated planned merger agreement

 

effective February 28, 2026

  • Company states it is actively pursuing alternative reverse-merger opportunities following termination of the Cullgen transaction.

Aardvark Therapeutics pauses Phase 3

 

Aardvark Therapeutics pauses Phase 3 HERO trial of ARD-101 in Prader-Willi after cardiac findings as RBC, Stifel, Morgan Stanley, HC Wainwright cut ratings

  • Pause followed reversible cardiac observations in an ARD-101 healthy volunteer study, which the company described as reversible.
  • Pause delays HERO trial's topline data timeline for ARD-101 in Prader-Willi syndrome.

Xeris beats, issues guidance

 

Xeris Biopharma beats Q4 estimates with non-GAAP EPS $0.06 and revenue $83.4M, issues 2026 revenue guidance of $375–$390M

  • Company reports a move to net profitability alongside record Q4 and full-year 2025 results.
  • 2026 outlook also calls for higher adjusted EBITDA.

Astrana Health guides 2026 revenue up ~24% and adjusted EBITDA up 29%

 

Astrana Health beats Q4 2025 estimates with non-GAAP EPS $0.12 (+180% YoY) and revenue $950.5M (+43% YoY), guides 2026 revenue up ~24% and adjusted EBITDA up 29%

  • Company will file Form 12b-25 for material weakness in internal controls over acquisition and purchase accounting processes.
  • Company's board of directors increased share repurchase authorization to $100 million.

uniQure says FDA finds AMT-130 Phase I/II data insufficient

 

 as 2025 results show loss and cash runway to 2H 2029

  • FDA deemed AMT-130 Phase I/II data versus an external control insufficient to support a marketing application.
  • Agency recommended a new randomized sham surgery-controlled trial, and uniQure plans further talks on Phase III design.
  • uniQure ended 2025 with $622.5 million in cash, expected to fund operations into the second half of 2029.
  • 2025 revenue totaled $16.1 million, while the company recorded a $199.0 million net loss for the year.